3CAI
CAS No. 28755-03-5
3CAI( —— )
Catalog No. M24203 CAS No. 28755-03-5
3CAI is a potent and specific AKT1 and AKT2 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | In Stock |
|
| 10MG | 63 | In Stock |
|
| 25MG | 114 | In Stock |
|
| 50MG | 209 | In Stock |
|
| 100MG | 313 | In Stock |
|
| 200MG | 460 | In Stock |
|
| 500MG | 746 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name3CAI
-
NoteResearch use only, not for human use.
-
Brief Description3CAI is a potent and specific AKT1 and AKT2 inhibitor.
-
Description3CAI is a potent and specific AKT1 and AKT2 inhibitor.
-
In Vitro3CAI is a potential inhibitor of AKT. Based on these screening data, the effect of 3CAI on the kinase activities of AKT1, MEK1, JNK1, ERK1 and TOPK is tested using in vitro kinase assays. The results show that 3CAI (1 μM) suppresses only AKT1 kinase activity and the other kinases tested are not affected by 3CAI. 3CAI is a much more potent AKT1 inhibitor than PI3K (60% inhibition at 1 vs 10 μM, respectively). 3CAI substantially suppresses AKT1 activity as well as AKT2 activity in a dose dependent manner. 3CAI inhibits down-stream targets of AKT and induces apoptosis. AKT-mediated phosphorlyation site of mTOR (Ser2448) and GSK3β (Ser9) are substantially decreased by 3CAI in a time-dependent manner. Furthermore, pro-apoptotic marker proteins p53 and p21 are also upregulated by 3CAI after 12 or 24 h of treatment. HCT116 and HT29 colon cancer cells are seeded on 6 cm dishes in 1% FBS/McCoy's 5A (HCT116) with 3CAI (4 μM), I3C or the AKT inhibitor and then incubated for 4 days. Results show that the number of apoptotic cells is significantly increased by 3CAI in HCT116 and HT29 colon cancer cells compared with untreated control cells.
-
In VivoTo examine the antitumor activity of 3CAI in vivo, HCT116 cancer cells are injected into the right flank of individual athymic nude mice. Mice are orally administered 3CAI at 20 or 30 mg/kg, I3C at 100 mg/kg, or vehicle 5 times a week for 21 days. Treatment of mice with 30 mg/kg of 3CAI significantly suppresses HCT116 tumor growth by 50% relative to the vehicle-treated group (p<0.05). Remarkably, mice seem to tolerate treatment with these doses of 3CAI without overt signs of toxicity or significant loss of body weight compared with vehicle-treated group. Expression of these AKT-target proteins is strongly suppressed by 30 mg/kg of 3CAI in tumor tissues.
-
Synonyms——
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetAkt
-
RecptorAkt1|Akt2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number28755-03-5
-
Formula Weight193.63
-
Molecular FormulaC10H8ClNO
-
Purity>98% (HPLC)
-
SolubilityDMSO:246 mg/mL (1270.46 mM; Need ultrasonic)
-
SMILESO=C(CCl)c1c[nH]c2c1cccc2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kim DJ, et al. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev Res (Phila). 2011 Nov;4(11):1842-51.
molnova catalog
related products
-
Cinobufotalin
Cinobufotalin is a main cardiac toxin in toad, it is a novel anti-HCC agent, it induces growth inhibition and apoptosis in cultured HCC cells through ceramide production.
-
Vevorisertib trihydr...
Vevorisertib trihydrochloride (ARQ 751 trihydrochloride) is a selective and potent inhibitor of pan-AKT and AKT1-E17K mutations, inhibiting AKT1, AKT2 and AKT3.
-
Guggulsterone E&Z
Guggulsterone E&Z?is a 3-hydroxy steroid. It has a role as an androgen.
Cart
sales@molnova.com